Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2016: International AIDS Conference Coming Up in Durban

The 21st International AIDS Conference (AIDS 2016) will take place July 18-22 in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.com and collaborator Aidsmap.com will provide comprehensive on-site coverage starting July 18. Follow @HIVandHepatitison Twitter and see our AIDS 2016 conference page (coming soon) or Facebook page for the latest news.

alt

Read more:

ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.

alt

Read more:

New California Grants Address Disparities in HIV Prevention and Care

An $9 million effort funded by the California HIV/AIDS Research Program (CHRP) will create new interventions tailored to reach heard-to-reach and heavily impacted groups living with or at risk for HIV, including homeless youth, HIV-positive young men of color, young people who use drugs or alcohol, the House Ball community, and women with barriers to care. The new initiative aims to increase HIV testing, treatment initiation, adherence to therapy, and retention in HIV care.

alt

Read more:

Coverage of ASM Microbe 2016 (ICAAC 2016)

HIVandHepatitis.com coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.

Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.

Full coverage listing by topic

ASM Microbe 2016 website

7/1/16

alt

Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART

The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.

alt

Read more:

ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.

alt

Read more:

ASM Microbe 2016: PRO-140 Antibody Injections Maintain Viral Suppression Off ART

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

alt

Read more: